Chlamydia trachomatis Pgp3 antibody population seroprevalence before and during an era of widespread opportunistic chlamydia screening in England (1994-2012)

Supporting Figure 1: Flow chart showing selection of stored sera from Health Survey for England (HSE) participants and inclusion in analyses

Key

- Included in analysis of age-specific Pgp3 seroprevalence over time
- Included in analysis of factors associated with Pgp3 seroprevalence
- Included in description of reported chlamydia diagnoses among Pgp3 seropositive

Note: analysis groups are not mutually exclusive, therefore sum of number in each group is greater than total number tested (n=5,618).